What is the competitive advantage of cells with frequently occurring mutations during tumor development? Vermeulen et al. quantified the advantages of Apc -loss, Kras activation, and P53 mutation during tumor initiation in the mouse intestine.
http://www.sciencemag.org/content/342/6161/995.short
http://www.sciencemag.org/content/342/6161/995.short
No comments:
Post a Comment